Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine Sublingual Safety Study in MDD
NCT01156415Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Novartis. Primary endpoint: Reports of adverse events, serious adverse events, changes in laboratory values, ECGs, vital signs, physical examination, and Columbia Suicidality Severity Rating Scale at 52 weeks. Started Jun 2010; status: terminated.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01156415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01156415.